Protara Therapeutics, Inc. (TARA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 53.23M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 4.84M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -76.79M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $53.23M | (m) | $4.84M | $-76.79M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $47.05M | (m) | $4.36M | $-70.05M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $42.63M | (m) | $3.83M | $-64.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $39.01M | (m) | $3.69M | $-59.78M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $37.49M | (m) | $3.57M | $-57.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $33.10M | (m) | $3.73M | $-51.43M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $31.70M | (m) | $4.13M | $-49.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $28.59M | (m) | $4.67M | $-45.88M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $26.73M | (m) | $5.19M | $-44.25M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $27.59M | (m) | $5.74M | $-45.73M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $24.99M | (m) | $6.09M | $-43.61M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $23.60M | (m) | $6.07M | $-72.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $20.84M | (m) | $6.06M | $-69.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $16.68M | (m) | $6.38M | $-65.92M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $16.81M | (m) | $6.69M | $-67.06M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $15.89M | (m) | $7.17M | $-37.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $16.51M | (m) | $8.45M | $-40.70M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $19.32M | (m) | $9.50M | $-44.78M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $21.09M | (m) | $10.36M | $-47.49M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-09-30 | $20.67M | (m) | $10.79M | $-46.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $19.38M | (m) | $10.86M | $-43.39M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $15.96M | (m) | $9.69M | $-37.86M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $11.98M | (m) | $9.75M | $-34.44M | $34.00K | (m) | (m) | -1013.06× | Reported |
| 2020-09-30 | $11.61M | (m) | $8.03M | $-35.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $9.91M | (m) | $5.39M | $-29.72M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $8.42M | (m) | $3.66M | $-23.89M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $6.44M | (m) | $943.00K | $-15.25M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $9.04M | (m) | $1.76M | $-19.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $11.19M | (m) | $2.57M | $-22.03M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $11.82M | (m) | $3.39M | $-21.64M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $11.85M | (m) | $3.43M | $-21.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $12.40M | (m) | $3.42M | $-21.58M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $20.38M | (m) | $3.26M | $-29.26M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $21.51M | (m) | $3.20M | $-30.25M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $21.69M | (m) | $3.23M | $-30.36M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $22.91M | (m) | $3.30M | $-31.64M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $17.42M | (m) | $3.24M | $-26.50M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $18.77M | (m) | $3.32M | $-28.37M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $18.87M | (m) | $3.34M | $-28.70M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $18.01M | (m) | $3.17M | $-28.03M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $16.25M | (m) | $3.09M | $-25.94M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $14.10M | (m) | $2.62M | $-23.07M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $12.38M | (m) | $2.16M | $-20.87M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $10.68M | (m) | $1.72M | $-17.96M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $9.37M | (m) | $1.29M | $-12.74M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $7.88M | (m) | $849.00K | $-10.27M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $6.43M | $2.95M | $459.00K | $-7.58M | $857.00K | 218.18% | 15.57% | -8.84× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $3.99M | (m) | $155.00K | $-7.12M | $861.00K | (m) | (m) | -8.27× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $5.91M | (m) | $110.00K | $-8.00M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |